Gingivax LLC is a new company centered around the benefits of the oral microbiome, and it is investigating oral bacteria as a potential source of new adjuvants. Molecules extracted from these bacteria, which can activate crucial Th17 cells, could be added to vaccines to increase their efficacy.
HAMPTON, N.J., June 3, 2021 (SEND2PRESS NEWSWIRE) — Three researchers have published a groundbreaking paper on the importance of oral bacteria in the fight against infectious diseases like influenza, HIV, and COVID-19, Gingivax LLC announced today.
